Skip to main content
. 2018 Jul;366(1):145–157. doi: 10.1124/jpet.118.249250

Fig. 8.

Fig. 8.

Antagonism by βCCT and flumazenil of zolpidem- and HZ-166-induced changes in tactile/oral exploration. Other details as in Fig. 7. Left panel: Zolpidem (“Zolp”) at a lower dose (1.0 mg/kg, i.v.) enhanced tactile/oral exploration that was blocked by both flumazenil (“Flum,” 0.3 mg/kg, i.v.) and βCCT (3.0 mg/kg, i.v.); center panel: Zolpidem at a higher dose (10 mg/kg, i.v.) attenuated tactile/oral exploration, which was reversed by flumazenil (0.3 mg/kg, i.v.) but not βCCT (3.0 mg/kg, i.v.); right panel: HZ-166 (30 mg/kg, i.v.) attenuated tactile/oral exploration that was reversed by flumazenil (0.3 mg/kg, i.v.) but not βCCT (3.0 mg/kg, i.v.). Note that *P ≤ 0.05 vs. vehicle (Veh) or “Zolp” condition, Bonferroni t tests, n = 4 monkeys.